International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 3 May-June 2023, pp: 807-816 www.ijprajournal.com ISSN: 2249-7781

WHO guideline on Current Good Manufacturing Practices for Herbal medicines

Prof. (Dr.) Mohd Wasiullah[1], Piyush Yadav[*2], Sushil Yadav[3], Abhishek Rai[4]
1. Principal, Dept. of Pharmacy, Prasad Institute of Technology, Jaunpur (222001) U.P, India.
2. Principal, Dept. of Pharmacy, Prasad Polytechnic, Kanpur (222001) U.P, India.
3. Assistant Professor, Dept. of Pharmacy, Prasad Institute of Technology, Jaunpur (222001) U.P, India.
4. Department of Pharmacy, Prasad Institute of Technology, Jaunpur (222001) U.P, India.

Submitted: 05-05-2023 Accepted: 15-05-2023

ABSTRACT:
The World Health Organization (WHO) has pulished guidelines on Current Good Manufacturing Practices (cGMP) for herbal medicines. The guidelines aim to provide recommendations for the manufacturing, packaging, labeling, and storage of herbal medicines, with the ultimate goal of ensuring their quality, safety, and efficacy.
The guidelines outline the essential components of cGMP for herbal medicines, including quality control, facility design and maintenance, equipment and materials, personnel, documentation, and complaint handling. They also provide specific guidance on the processing of herbal materials, preparation of herbal extracts, and the formulation of herbal products.
Keyword: cGMP ,quality control ,quality assurance ,WHO, validation.

I. INTRODUCTION:

The WHO guide to current good manufacturing practice (cGMP) requirements is a set of guidelines developed by the World Health Organization (WHO) to ensure that pharmaceutical products are consistently manufactured to a high quality standard, in order to protect public health. The purpose of this guide is to provide manufacturers with a comprehensive set of cGMP requirements and recommendations that should be followed throughout the entire manufacturing process. The guidelines cover all aspects of pharmaceutical manufacturing, including quality control, personnel, equipment, documentation, and record keeping. The ultimate goal of these guidelines is to ensure that pharmaceutical products are manufactured consistently, with high quality and safety standards, and to minimize the risks of product contamination, mix-ups, and errors that could lead to harm to patients. By following the WHO cGMP guidelines, manufacturers can ensure that their products are of the highest quality and meet the required safety and efficacy standards. Additionally, the guidelines also help regulators to evaluate manufacturers' compliance with cGMP requirements, thus ensuring that the products on the market are safe and effective for patients to use.

Current good manufacturing practices:

Fig-1 Current Good Manufacturing Practice

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 3 May-June 2023, pp: 807-816 www.ijprajournal.com ISSN: 2249-7781

Current Good Manufacturing Practices (cGMP) are a set of guidelines and regulations that are followed by pharmaceutical, medical device, and food industries to ensure the safety, quality, and efficacy of their products. The cGMP regulations are enforced by regulatory agencies such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

The main objectives of cGMP are:

To establish and maintain a quality management system

To ensure that products are consistently produced and controlled to meet quality standards

To ensure that all manufacturing processes are validated and documented

To ensure that equipment is properly maintained and calibrated

To ensure that personnel are properly trained and qualified

To ensure that raw materials, packaging materials, and finished products are properly identified, stored, and handled

To ensure that all deviations from established procedures are investigated and documented

To ensure that all products are properly labeled and packaged

To ensure that records are maintained and retained in accordance with applicable regulations

To ensure that all products are tested for quality and safety before release to the market.

Compliance with cGMP is essential to ensure that products are safe, effective, and of high quality. Non-compliance can result in product recalls, legal action, and damage to the reputation of the company. Therefore, adherence to cGMP is a critical aspect of the manufacturing process in industries regulated by the FDA and other regulatory agencies.

Current good manufacturing practices Type

There are several types of Current Good Manufacturing Practices (cGMP), depending on the industry and the product being manufactured. Some examples of cGMP types include:

Pharmaceutical cGMP: These are regulations and guidelines that apply to the manufacturing of pharmaceutical products, including drugs, biologics, and vaccines. The pharmaceutical cGMP regulations are enforced by regulatory agencies such as the FDA and the EMA.

Medical Device cGMP: These are regulations and guidelines that apply to the manufacturing of medical devices, including diagnostic equipment, surgical instruments, and implants. The medical device cGMP regulations are also enforced by the FDA.

Food cGMP: These are regulations and guidelines that apply to the manufacturing of food products, including food additives, dietary supplements, and infant formula. The food cGMP regulations are enforced by regulatory agencies such as the FDA and the U.S. Department of Agriculture (USDA).

Cosmetic cGMP: These are regulations and guidelines that apply to the manufacturing of cosmetic products, including makeup, skincare, and haircare products. The cosmetic cGMP regulations are enforced by the FDA.

Veterinary cGMP: These are regulations and guidelines that apply to the manufacturing of animal drugs, feed, and other veterinary products. The veterinary cGMP regulations are enforced by regulatory agencies such as the FDA and the European Medicines Agency (EMA).

These cGMP types ensure that products are manufactured under a set of guidelines that are specific to the industry and product type, and help to ensure that the products are safe, effective, and of high quality.

Some of the key principles of cGMPs include:

Quality control: All materials and products should be tested and verified for quality and purity. Quality control is an essential component of Current Good Manufacturing Practices (CGMPs). Quality control measures ensure that products are manufactured to meet established specifications and are safe and effective for their intended use.

The following are key aspects of quality control for CGMP compliance:

Product Specification: The product specification defines the quality attributes of the product, including its identity, strength, purity, and potency. The specification must be established based on the intended use of the product, and must be scientifically justified and validated.

In-process Control:

In-process control measures are performed during the manufacturing process to ensure that the product is meeting the established specifications. In-process control tests may include checks on the physical and chemical properties of the product, as well as checks on the equipment used in the manufacturing process.

Final Product Testing: Final product testing is performed to ensure that the finished product meets the established specifications. Final product tests

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 3 May-June 2023, pp: 807-816 www.ijprajournal.com ISSN: 2249-7781

may include checks on the identity, strength, purity, and potency of the product.

Stability Testing: Stability testing is performed to evaluate the stability of the product over time under various storage conditions. Stability testing ensures that the product maintains its quality attributes throughout its shelf life.

Quality Assurance: Quality assurance is responsible for ensuring that all quality control measures are properly performed and documented. Quality assurance personnel are responsible for reviewing and approving product specifications, in-process control tests, final product testing, and stability testing.

Out-of-Specification (OOS) Investigations: OOS investigations are performed when a product fails to meet established specifications. OOS investigations determine the cause of the failure and ensure that corrective actions are taken to prevent similar failures in the future.

Validation: Validation is the process of establishing documented evidence that a process or test method consistently produces results that meet predetermined specifications. Validation is required for all critical processes and test methods.

Process validation: Manufacturing processes should be validated to ensure that they are capable of consistently producing high-quality products.

Documentation: Detailed records should be kept of all manufacturing processes, including testing and validation data. Documentation is a critical aspect of compliance with Current Good Manufacturing Practices (CGMPs). Proper documentation ensures that manufacturing processes are controlled and validated, and that products are consistently produced according to established specifications.

The following are some key documentation requirements for CGMP compliance:

Standard Operating Procedures (SOPs): SOPs are written procedures that provide step-by-step instructions for performing specific manufacturing or laboratory activities. SOPs must be available and up to date for all critical activities, and personnel must be trained to follow them.

Batch Records: Batch records document the details of the manufacturing process for a specific batch of a product. They include information on the materials used, processing parameters, and quality control tests performed. Batch records must be accurate, complete, and available for review.

Validation Documents: Validation documents provide evidence that a manufacturing process or analytical method has been validated and is capable of producing consistent results. Validation documents include protocols, reports, and other documentation that demonstrates the validation process.

Change Control Records: Change control records document any changes made to a manufacturing process or analytical method, including the reason for the change, the impact on the product, and the approval process for the change.

Equipment Calibration and Maintenance Records: Equipment calibration and maintenance records document the calibration and maintenance activities performed on manufacturing and laboratory equipment. These records ensure that equipment is in good working order and producing accurate results.

Training Records: Training records document the training provided to personnel involved in manufacturing and laboratory activities. These records ensure that personnel are adequately trained to perform their tasks and that training is up to date.

Complaint and Investigation Records: Complaint and investigation records document any complaints received from customers and any investigations performed to determine the cause of the complaint. These records help identify potential issues and ensure that corrective actions are taken when necessary. Complaint and investigation records are an important aspect of Current Good Manufacturing Practices (CGMPs).These records document any complaints or quality issues related to a product and the resulting investigation to determine the root cause and corrective actions.

The following are key aspects of complaint and investigation records for CGMP compliance:

1. Complaint Handling Procedures: A documented complaint handling procedure should be established, describing the steps and responsibilities for receiving, investigating, and resolving product complaints. The procedure should also describe the documentation requirements for complaints.

2. Complaint Investigation: Complaints should be investigated to determine the root cause and corrective actions required to prevent recurrence. The investigation should include an evaluation of the impact of the complaint on product quality and safety.

3. Corrective Actions: Corrective actions should be implemented to address the root cause of the complaint and prevent recurrence. Corrective actions should be documented and tracked to completion.

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 3 May-June 2023, pp: 807-816 www.ijprajournal.com ISSN: 2249-7781

4. Trend Analysis: Complaint and investigation records should be analyzed to identify trends and potential quality issues. Trend analysis should be used to identify areas for improvement in the manufacturing process.

5. Regulatory Reporting: Certain product complaints may require reporting to regulatory agencies. Facilities should establish procedures for reporting product complaints to regulatory agencies.

6. Record Retention: Complaint and investigation records should be retained for a defined period, as required by regulatory agencies. Proper complaint handling and investigation procedures are essential to ensure that quality issues are identified, investigated, and resolved. CGMP compliance requires that documented complaint handling procedures be established and followed for all product complaints.

Investigation of complaints, implementation of corrective actions, trend analysis, regulatory reporting, and record retention are key aspects of complaint and investigation records for CGMP compliance. Documentation for CGMP compliance must be accurate, complete, and available for review.

It is important to establish and follow procedures for creating, maintaining, and reviewing documentation to ensure compliance with regulatory requirements.

Training: All personnel involved in manufacturing should be trained and qualified to perform their duties. Training is an essential component of Current Good Manufacturing Practices (CGMPs). Proper training ensures that personnel involved in manufacturing and laboratory activities are knowledgeable and competent to perform their tasks. The following are key aspects of training for CGMP compliance:

1. Personnel Qualification: Personnel involved in manufacturing and laboratory activities must be qualified and trained for their specific tasks. Qualification and training should be documented and reviewed periodically to ensure that personnel maintain their knowledge and skills.

2. GMP Training: Personnel involved in manufacturing and laboratory activities must receive GMP training that covers the regulatory requirements for CGMP compliance. The training should include an overview of the regulations, as well as the specific requirements for their job responsibilities.

3. Job-Specific Training: Personnel involved in manufacturing and laboratory activities must receive job-specific training that covers the procedures and processes relevant to their job responsibilities. Job-specific training should include hands-on training and should be documented.

4. Refresher Training: Personnel involved in manufacturing and laboratory activities must receive refresher training periodically to ensure that they maintain their knowledge and skills. Refresher training should be documented and scheduled at appropriate intervals.

5.Training Records: Training records must be maintained for all personnel involved in manufacturing and laboratory activities. Training records should include the name of the employee, the date of the training, the content of the training, and the signature of the trainer and trainee.

6. Training Effectiveness: The effectiveness of the training program should be evaluated periodically to ensure that personnel are adequately trained and that the training program is meeting its objectives. The evaluation should include feedback from personnel and a review of training records. Proper training is essential to ensuring that personnel involved in manufacturing and laboratory activities are knowledgeable and competent to perform their tasks.

CGMP compliance requires that training be established, documented, and reviewed periodically to ensure that personnel maintain their knowledge and skills.

Facility and equipment maintenance: Facilities and equipment used in manufacturing should be regularly maintained and cleaned to ensure that they are in good working condition.Facility and equipment maintenance are important aspects of Current Good Manufacturing Practices (CGMPs). Proper maintenance ensures that the facility and equipment used in manufacturing are operating correctly and producing products that meet established specifications.

The following are key aspects of facility and equipment maintenance for CGMP compliance:

1. Preventive Maintenance: Preventive maintenance is the regular maintenance of equipment and facilities to prevent breakdowns and ensure that they are operating correctly. Preventive maintenance should be documented and performed at scheduled intervals.

2. Calibration: Calibration is the process of verifying and adjusting equipment to ensure that it is producing accurate and reliable results.

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 3 May-June 2023, pp: 807-816 www.ijprajournal.com ISSN: 2249-7781

Calibration should be performed at scheduled intervals and should be documented.

3. Cleaning and Sanitization: Cleaning and sanitization are critical for preventing contamination of products. Facilities and equipment should be cleaned and sanitized at scheduled intervals, using appropriate cleaning agents and methods. Cleaning and sanitization procedures should be documented.

4. Repairs and Modifications: Repairs and modifications to equipment and facilities should be performed by qualified personnel, using appropriate procedures and documentation. Modifications should be validated to ensure that they do not affect product quality.

5. Facility and Equipment Monitoring: Facilities and equipment should be monitored regularly for environmental factors, such as temperature, humidity, and air quality. Monitoring should be documented and reviewed periodically to ensure that the facility and equipment are operating within established specifications.

6. Records and Documentation: Maintenance records and documentation should be maintained for all equipment and facilities. Documentation should include maintenance and calibration schedules, cleaning and sanitization procedures, repair and modification records, and monitoring records.

Proper facility and equipment maintenance is essential to ensuring that products are manufactured in a safe and effective manner. CGMP compliance requires that facilities and equipment be maintained, calibrated, and cleaned at scheduled intervals, with appropriate documentation and records.

Sanitation: Manufacturing facilities should be kept clean and free of contaminants to prevent contamination of products. Sanitation is an important aspect of Current Good Manufacturing Practices (CGMPs). Sanitation refers to the process of cleaning and disinfecting equipment, facilities, and surfaces to prevent contamination of products.

The following are key aspects of sanitation for CGMP compliance:

1. Cleaning Procedures: Cleaning procedures should be established for all equipment, facilities, and surfaces that come into contact with products. The procedures should include the type of cleaning agent used, the cleaning method, and the frequency of cleaning. The cleaning procedures should be documented.

2. Disinfection Procedures: Disinfection procedures should be established for all equipment, facilities, and surfaces that require disinfection. The procedures should include the type of disinfectant used, the concentration, and the contact time. The disinfection procedures should be documented.

3. Validation of Cleaning and Disinfection Procedures: Cleaning and disinfection procedures should be validated to ensure that they are effective in removing contaminants. Validation should include testing for residual contamination and verification of the effectiveness of the cleaning and disinfection procedures.

4. Personnel Hygiene: Personnel should follow good hygiene practices, including proper handwashing, wearing clean clothing, and avoiding contact with products when ill. Facilities should provide training to personnel on proper hygiene practices.

5. Pest Control: Facilities should establish procedures to control pests, including insects, rodents, and birds. Procedures should include monitoring, trapping, and use of approved pesticides.

6. Environmental Monitoring: Facilities should conduct environmental monitoring to ensure that facilities and equipment are clean and free from contamination. Monitoring should include testing for microorganisms, particulates, and other contaminants.

Proper sanitation procedures are essential to ensure that products are manufactured in a safe and effective manner. CGMP compliance requires that facilities establish and follow documented sanitation procedures for equipment, facilities, and surfaces that come into contact with products.Validation of cleaning and disinfection procedures, personnel hygiene, pest control, and environmental monitoring are key aspects of sanitation for CGMP compliance.

Change control: Any changes to manufacturing processes, equipment, or facilities should be documented, reviewed, and approved before implementation. Change control is an essential aspect of Current Good Manufacturing Practices (CGMPs). Change control procedures are used to manage changes to processes, equipment, facilities, materials, and documentation to ensure that they do not impact product quality.

The following are key aspects of change control for CGMP compliance:

1. Change Control Procedures: A documented change control procedure should be established,

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 3 May-June 2023, pp: 807-816 www.ijprajournal.com ISSN: 2249-7781

describing the steps and responsibilities for initiating, evaluating, approving, implementing, and verifying changes. The procedure should also describe the documentation requirements for changes.

2. Change Requests: Change requests should be initiated for any proposed changes to processes, equipment, facilities, materials, or documentation. Change requests should include a description of the change, the reason for the change, the impact of the change, and a proposed timeline for implementation.

3. Change Evaluation: Changes should be evaluated for their impact on product quality, safety, and efficacy. An assessment should be conducted to determine if the change requires validation, re-validation, or qualification.

4. Change Approval: Changes should be approved by authorized personnel, based on the evaluation of the change request. The approval should be documented and should include a description of the change, the reason for the change, and the impact of the change.

5. Change Implementation: Changes should be implemented according to the approved change control plan. The implementation should be documented, including any deviations from the plan and any corrective actions taken.

6. Change Verification: Changes should be verified to ensure that they have been implemented correctly and do not impact product quality. Verification should be documented, including any testing or sampling performed.

7. Change Closure: Change control records should be closed after the change has been verified and approved. The records should be maintained for a defined period, as required by regulatory agencies.

Proper change control procedures are essential to ensure that changes to processes, equipment, facilities, materials, and documentation are managed appropriately and do not impact product quality. CGMP compliance requires that documented change control procedures be established and followed for all changes. Adherence to cGMPs is critical for ensuring the safety and efficacy of pharmaceutical, biotech, and medical device products, and regulatory agencies regularly inspect manufacturing facilities to ensure compliance.

Validation: Validation is an important aspect of current good manufacturing practice (cGMP) requirements in the pharmaceutical industry. Validation refers to the process of establishing documented evidence which provides a high degree of assurance that a specific process or equipment will consistently produce a product that meets its predetermined specifications and quality attributes.

In the context of a WHO guide to cGMP requirements, validation would involve ensuring that the manufacturing processes used to produce pharmaceutical products comply with cGMP standards, and that the final products meet the required quality and safety standards.

Validation activities typically include the following steps:

Planning and defining the scope of the validation process. Conducting a risk assessment to identify potential hazards and critical process parameters. Developing a validation protocol that outlines the testing procedures, acceptance criteria, and documentation requirements. Executing the validation protocol, which may involve testing equipment, processes, or finished products. Analyzing the data collected during the validation process and documenting the results. Reviewing and approving the validation report.

Validation is an ongoing process that requires continuous monitoring and re-evaluation to ensure that processes remain in a state of control and continue to produce high-quality products. It is an essential component of cGMP compliance and is critical to ensuring the safety, efficacy, and quality of pharmaceutical products. Protocols CGMP, or Current Good Manufacturing Practice, refers to a set of regulations established by the US Food and Drug Administration (FDA) that ensure the quality, safety, and efficacy of pharmaceuticals, medical devices, and dietary supplements.

The following are some of the key protocols for CGMP:

1. Quality control and assurance: CGMP requires that pharmaceutical companies establish and maintain a robust quality control system to ensure that their products meet the required standards of quality, purity, and potency. This includes rigorous testing and documentation of all raw materials, intermediates, and finished products.

2. Standard operating procedures (SOPs): CGMP regulations require that pharmaceutical companies establish and maintain standard operating procedures (SOPs) for all aspects of manufacturing and testing. SOPs should be well-documented, regularly updated, and followed strictly to ensure consistency and compliance with regulations. An SOP (Standard Operating Procedure) for CGMP outlines the specific

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 3 May-June 2023, pp: 807-816 www.ijprajournal.com ISSN: 2249-7781

procedures and guidelines that must be followed in a manufacturing or laboratory setting to ensure compliance with current Good Manufacturing Practices (cGMPs).

The following are some key components that should be included in an SOP for CGMP:

i. Purpose: The purpose of the SOP should be clearly stated, including its relevance to the manufacturing process or laboratory operation being performed.
ii. Scope: The scope of the SOP should be defined, including the specific areas and activities it applies to, such as equipment operation, material handling, and testing procedures.
iii. Responsibilities: The roles and responsibilities of personnel involved in the activity should be clearly outlined, including who is responsible for performing the task, who is responsible for monitoring and reviewing the results, and who is responsible for approving the task.
iv. Procedures: The procedures for the activity should be clearly defined, including the steps that must be followed, the materials and equipment required, and any special precautions that must be taken.
v. Training: The training requirements for personnel involved in the activity should be outlined, including the training necessary to perform the activity and the frequency of refresher training.
vi. Documentation: The documentation requirements for the activity should be clearly defined, including the forms, records, and reports that must be completed, reviewed, and approved.
vii. Change control: The procedures for managing changes to the SOP should be clearly defined, including how changes will be proposed, reviewed, and approved. viii.
viii. Deviation management: The procedures for managing deviations from the SOP should be clearly outlined, including how deviations will be reported, investigated, and resolved. ix.
ix. Review and Approval: The review and approval process for the SOP should be outlined, including who is responsible for reviewing and approving the SOP, and how often the SOP will be reviewed and updated. x.
x. References: The SOP should include any applicable regulations, guidelines, or standards that the activity must comply with. An SOP for CGMP is an important document that ensures that manufacturing and laboratory operations are performed in a consistent and controlled manner in compliance with regulatory requirements. It provides clear instructions for personnel involved in the activity and helps to ensure product quality and safety.

3. Facility design and control: CGMP requires that pharmaceutical companies establish and maintain appropriate facilities, equipment, and control systems to ensure that the manufacturing process is carried out in a safe and controlled environment. This includes controlling temperature, humidity, and other environmental factors, as well as preventing contamination of products. Facility design and control for CGMP (Current Good Manufacturing Practices) is critical in ensuring that pharmaceutical and biotech products are manufactured in a consistent, safe, and effective manner.

The following are some important considerations when designing and controlling a facility for CGMP:

1. Facility Design: The facility should be designed to prevent contamination and facilitate cleaning. This includes proper air handling systems, flooring, walls, ceilings, and doors. The facility should also be designed to allow for the segregation of different operations to prevent crosscontamination.

2. Equipment Design and Control: Equipment used in the manufacturing process should be designed and controlled to prevent contamination. This includes equipment selection, installation, and maintenance.

3. Personnel: Personnel should be trained and qualified to perform their duties in a manner that prevents contamination. This includes training on proper gowning, hygiene, and procedures.

4. Standard Operating Procedures (SOPs): The facility should have clearly defined and documented SOPs for all manufacturing processes, including cleaning, equipment use, and personnel procedures.

5. Quality Control: The facility should have a robust quality control program in place to ensure that all products meet their intended specifications. This includes testing of raw materials, inprocess testing, and finished product testing.

6. Environmental Monitoring: The facility should have an environmental monitoring program in place to detect and control any potential contamination. This includes monitoring of air, water, and surfaces.

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 3 May-June 2023, pp: 807-816 www.ijprajournal.com ISSN: 2249-7781

7. Validation: The facility and processes should be validated to ensure that they are capable of consistently producing products that meet their intended specifications.

Overall, facility design and control for CGMP is a critical component of ensuring the safety and efficacy of pharmaceutical and biotech products. It requires careful planning, implementation, and monitoring to ensure that all processes are performed in a consistent and controlled manner.

4. Personnel training: CGMP requires that pharmaceutical companies provide adequate training to all personnel involved in the manufacturing and testing of pharmaceutical products. This includes training in good manufacturing practices, SOPs, and regulatory requirements.

5. Documentation:CGMP regulations require that pharmaceutical companies maintain detailed records of all manufacturing and testing activities, including batch records, test results, and documentation of any deviations from established procedures. Documentation is a critical aspect of compliance with Current Good Manufacturing Practices (CGMPs).

Proper documentation ensures that manufacturing processes are controlled and validated, and that products are consistently produced according to established specifications.

The following are some key documentation requirements for CGMP compliance:

1. Standard Operating Procedures (SOPs): SOPs are written procedures that provide step-by-step instructions for performing specific manufacturing or laboratory activities. SOPs must be available and up to date for all critical activities, and personnel must be trained to follow them.

2. Batch Records: Batch records document the details of the manufacturing process for a specific batch of a product. They include information on the materials used, processing parameters, and quality control tests performed. Batch records must be accurate, complete, and available for review.

3. Validation Documents: Validation documents provide evidence that a manufacturing process or analytical method has been validated and is capable of producing consistent results. Validation documents include protocols, reports, and other documentation that demonstrates the validation process.

4. Change Control Records: Change control records document any changes made to a manufacturing process or analytical method, including the reason for the change, the impact on the product, and the approval process for the change.

5. Equipment Calibration and Maintenance Records: Equipment calibration and maintenance records document the calibration and maintenance activities performed on manufacturing and laboratory equipment. These records ensure that equipment is in good working order and producing accurate results.

6. Training Records: Training records document the training provided to personnel involved in manufacturing and laboratory activities. These records ensure that personnel are adequately trained to perform their tasks and that training is up to date.

7. Complaint and Investigation Records: Complaint and investigation records document any complaints received from customers and any investigations performed to determine the cause of the complaint. These records help identify potential issues and ensure that corrective actions are taken when necessary. Documentation for CGMP compliance must be accurate, complete, and available for review.

It is important to establish and follow procedures for creating, maintaining, and reviewing documentation to ensure compliance with regulatory requirements.

6. Complaint handling: CGMP regulations require that pharmaceutical companies establish and maintain procedures for handling complaints related to their products. This includes investigating and resolving complaints in a timely and effective manner.

7. Validation and verification: CGMP regulations require that pharmaceutical companies validate and verify all processes, methods, and equipment used in the manufacturing and testing of pharmaceutical products. This includes conducting appropriate validation studies and verifying that processes are operating within established parameters.

Validation Analytical Assay

Analytical assay validation is a crucial process that ensures the reliability and accuracy of the results generated from an analytical method. The validation process evaluates various aspects of the analytical method, such as specificity, accuracy, precision, linearity, range, and robustness, to ensure that the method is suitable for its intended use.

The validation process typically involves the following steps:

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 3 May-June 2023, pp: 807-816 www.ijprajournal.com ISSN: 2249-7781

Define the purpose and scope of the method: Clearly state the intended use of the method and the type of samples that will be tested.
Method development: Develop and optimize the analytical method to ensure that it is reliable, accurate, and precise.
Specificity: Evaluate the ability of the method to detect and quantify the analyte of interest in the presence of other potential interfering substances.
Accuracy: Determine the closeness of agreement between the measured value and the true value of the analyte.
Precision: Evaluate the repeatability and intermediate precision of the method by analyzing replicate samples.
Linearity: Determine the range of concentrations over which the method provides accurate and precise measurements.
Range: Determine the minimum and maximum concentrations that can be measured by the method.
Robustness: Evaluate the effect of minor variations in the analytical conditions on the results.
System suitability: Determine whether the analytical system is performing within acceptable limits before sample analysis.
Documentation: Document the validation process, including all data and results obtained, in a validation report.
In summary, the validation of an analytical assay is a comprehensive process that involves evaluating various aspects of the method to ensure that it is suitable for its intended use. Proper validation of an analytical method is essential to ensure that the data generated from the method is reliable and can be used with confidence in decision-making processes.

II. CONCULSION

As an AI language model, I do not have access to the latest information on the WHO guideline on current good manufacturing practices for herbal medicines beyond my knowledge cutoff date of 2021. However, I can provide a general overview of the guideline based on the information available up to that point.

The WHO guideline on current good manufacturing practices for herbal medicines provides a framework for ensuring the quality, safety, and efficacy of herbal medicines. It aims to establish minimum requirements for the manufacture, quality control, and distribution of herbal medicines, including raw materials, finished products, and packaging materials.

The guideline covers a range of topics, including personnel, premises, equipment, documentation, production, quality control, and distribution. It emphasizes the importance of using validated methods and procedures to ensure the consistency and reliability of herbal medicines, and the need for regular monitoring and evaluation to identify and address any potential risks or issues.

Overall, the WHO guideline on current good manufacturing practices for herbal medicines is an important tool for ensuring that herbal medicines are produced to a high standard and can be used safely and effectively by patients around the world.

REFERENCE: -

[1]. Aerts J, Ballinger JR, Behe M, Decristoforo C, Elsinga PH, Faivre-Chauvet A, Mindt TL, Kolenc Peitl P, Todde S, Koziorowski J. Guidance on current good radiopharmacy practice for the small-scale preparation of radiopharmaceuticals using automated modules: a European perspective. J Labelled Compd Radiopharm. 2014;57:615–20.
[2]. de Vries EJF, Roca M, Jamar F, Israel O, Signore A. Guidelines for the labelling of leucocytes with 99mTc-HMPAO. Eur J Nucl Med Mol Imaging. 2010; 37:842–8.
[3]. Elsinga P, Todde S, Penuelas I, Meyer G, Farstad B, Faivre-Chauvet A, Mikolajczak R, Westera G, Gmeiner-Stopar T, Decristoforo C. Guidance on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals. Eur J Nucl Med Mol Imaging. 2010;37(5):1049–62.
[4]. Gillings N, Todde S, Behe M, Decristoforo C, Elsinga P, Ferrari V, Hjelstuen O, Kolenc Peitl P, Koziorowski J, Laverman P, Mindt TL, Ocak M, Patt M. EANM Guideline on the Validation of Analytical Methods for Radiopharmaceuticals EJNMMI Radiopharmacy and Chemistry. EJNMMI radiopharm. Chem. 2020;5:7.
[5]. Roca M, de Vries EF, Jamar F, Israel O, Signore A. Guidelines for the labelling of leucocytes with 111 In-oxine. Inflammation/Infection Taskgroup of the European Association of Nuclear Medicine. Eur J Nucl Med Mol Imaging. 2010;37(4):835–41.

[6]. Todde S, Kolenc Peitl P, Elsinga P, Koziorowski J, Ferrari V, Ocak EM, Hjelstuen O, Patt M, Mindt TL, Behe M. Guidance on validation and qualification of processes and operations involving radiopharmaceuticals. EJNMMI radiopharm. chem. 2017;2:8.
[7]. Choi, E. J. & Ling, G. S. Battlefield medicine: paradigm shift for pharmaceuticals manufacturing. PDA J. Pharm. Sci. Technol. 68, 312 (2014).
[8]. Schellekens, H., Aldosari, M., Talsma, H. & Mastrobattista, E. Making individualized drugs a reality. Nat. Biotechnol. 35, 507–514 (2017).
[9]. Editorial. Patient-centered drug manufacture. Nat. Biotechnol. 35, 485 (2017).
[10]. Adamo, A. et al. On-demand continuous-flow production of pharmaceuticals in a compact, reconfigurable system. Science 352, 61–67 (2016).
[11]. Smith, M. T., Wilding, K. M., Hunt, J. M., Bennett, A. M. & Bundy, B. C. The emerging age of cell-free synthetic biology. FEBS Lett. 588, 2755–2761 (2014).
[12]. Zemella, A., Thoring, L., Hoffmeister, C. & Kubick, S. Cell-free protein synthesis: pros and cons of prokaryotic and eukaryotic systems. ChemBioChem 16, 2420–2431 (2015).
[13]. Tran, K. et al. Cell-free production of a therapeutic protein: expression, purification, and characterization of recombinant streptokinase using a CHO lysate. Biotechnol. Bioeng. 115, 92–102 (2018).
[14]. Martin, R. W. et al. Development of a CHO-based cell-free platform for synthesis of active monoclonal antibodies. ACS Synth. Biol. 21, 1370–1379 (2017).
[15]. Boles, K. S. et al. Digital-to-biological converter for on-demand production of biologics. Nat. Biotechnol. 35, 672–675 (2017).
[16]. Pardee, K. et al. Portable, on-demand biomolecular manufacturing. Cell 167, 248–259 (2016).
[17]. Shukla, A. A., Hubbard, B., Tresses, T., Gihan, S. & Low, D. Downstream processing of monoclonal antibodies—application of platform approaches. Anal. Technol. Biomed. Life Sci. 15, 28–39 (2007).
[18]. Hammerling, U., Kroon, R. & Sjödin, L. In vitro bioassay with enhanced sensitivity for human granulocyte colony-stimulating factor. J. Pharm. Biomed. Anal. 13, 9–20 (1995).
[19]. Broder, A. K., Son abend, A. &Kubrick, S. Cell-free protein expression based on extracts from CHO cells. Biotechnol. Bioeng. 111, 25–36 (2014).
[20]. Peñalber-Johnstone, C. et al. Optimizing cell-free protein expression in CHO: assessing small molecule mass transfer effects in various reactor configurations. Biotechnol. Bioeng. 114, 1478–1486 (2017).
[21]. Tiangco, C. et al. Measuring transdermal glucose levels in neonates by passive diffusion: an in vitro porcine skin model. Anal. Bioanal. Chem. 409, 3475–3482 (2017).
[22]. Giannini, G., Rappuoli, R. & Ratti, G. The amino-acid sequence of two non-toxic mutants of diphtheria toxin: CRM45 and CRM197. Nucleic Acids Res. 12, 4063–4069 (1984).
[23]. Leader, B., Baca, Q. J. & Golan, D. E. Protein therapeutics: a summary and pharmacological classification. Nat. Rev. Drug Discov. 7, 21–39 (2008).
[24]. Gurramkonda, C. et al. Improving the recombinant human erythropoietin glycosylation using microsome supplementation in CHO cell-free system. Biotechnol. Bioeng. 115, 1253–1264 (2018).